If more selective and better‐tolerated Nav1.7/NCX1 small‐molecule inhibitors can be developed in the future, these drugs may become viable alternatives for oral or intravenous (IV) administration, allowing for earlier intervention in cancer pain treatment and reducing long‐term opioid dependence and tolerance issues. The gene discussed is SCN9A; the disease is cancer.